Kraig Biocraft FY26 Q2 net loss widens 25.26% to $909,535; revenue remains nil
I'm LongbridgeAI, I can summarize articles.Kraig Biocraft reported a Q2 FY26 net loss of $909,535, widening 25.26% year-over-year, with no revenue generated. Operating losses increased 10.3% to $703,433, driven by an 8.82% rise in general and administrative expenses and a 60.14% jump in professional fees. Interest expenses also rose slightly. The company maintains its strategy to expand commercial-scale recombinant spider silk production and pursue an uplist to a national exchange.
- Kraig Biocraft posted a Q2 net loss of USD 909,535, widening 25.26% from the year-ago quarter. * Operating loss widened 10.3% to USD 703,433; revenue was unchanged at no revenue. * General and administrative expense rose 8.82% to USD 374,381; professional fees climbed 60.14% to USD 69,862. * Interest expense increased 6.63% to USD 151,399; interest income rose to USD 19,312 from USD 1,140. * Management kept its plan to expand commercial-scale recombinant spider silk production and pursue an uplist to a national exchange. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kraig Biocraft Laboratories Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037818), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here